Global Liquid Biopsy Market Size & Forecast 2025–2033

The global liquid biopsy market is entering one of its most transformative growth phases ever recorded. According to Renub Research, the market is set to scale from US$ 4.29 billion in 2024 to an impressive US$ 15.46 billion by 2033, expanding at a vigorous CAGR of 15.30% during 2025–2033. This rapid expansion reflects unprecedented advancements in biomarker analysis, non-invasive cancer diagnostics, next-generation sequencing technologies, and the escalating demand for precision medicine worldwide.

Liquid biopsies—once considered an experimental innovation—have now become indispensable for early cancer detection, disease monitoring, treatment optimization, and even non-oncology applications such as prenatal screening and organ transplant assessment. As healthcare systems transition toward patient-centric, less invasive, and more efficient diagnostic models, liquid biopsy technologies are emerging as one of the fastest-growing pillars of modern medicine.

Download Free Sample Report

Understanding Liquid Biopsy: A Breakthrough in Modern Diagnostics

A liquid biopsy is a non-invasive diagnostic technique that analyzes circulating biomarkers present in body fluids—primarily blood, but also urine, saliva, and plasma. Unlike traditional tissue biopsies, which require surgical intervention to remove tissue samples, liquid biopsies rely on circulating biological traces released by tumors or damaged cells, including:

Cell-free DNA (cfDNA)

Circulating tumor DNA (ctDNA)

Circulating tumor cells (CTCs)

Exosomes and extracellular vesicles

These biomarkers give clinicians real-time visibility into tumor genetics, mutation patterns, and treatment resistance, enabling continuous patient monitoring with minimal risk. Whether assessing minimal residual disease (MRD) after treatment, predicting relapse, or detecting early-stage cancers, liquid biopsy is emerging as a revolutionary asset in precision oncology.

Beyond cancer, researchers are increasingly exploring its applications in prenatal aneuploidy testing, infectious disease detection, cardiovascular risk assessment, and transplant rejection monitoring—broadening market potential further.

Key Market Drivers Fueling Global Liquid Biopsy Growth

1. Rising Incidence of Cancer and Chronic Diseases

The global cancer burden continues to rise rapidly, creating unprecedented demand for early, accurate, and repeatable diagnostic solutions. In the United States alone, 2,001,140 new cancer cases and 611,720 cancer deaths were projected for 2024. Similar trends are evident across Europe, Asia-Pacific, and Latin America.

Liquid biopsies stand out for several reasons:

Non-invasive collection reduces patient discomfort and procedural risk

Rapid turnaround time accelerates diagnosis

Repeatability enables continuous monitoring

Earlier detection increases survival rates

Precision analytics improve treatment decision-making

Additionally, the ability of liquid biopsies to monitor cardiovascular, genetic, and metabolic conditions further widens their diagnostic scope.

2. Technological Advancements in Biomarker Discovery & Molecular Diagnostics

Breakthroughs in next-generation sequencing (NGS), digital PCR, and data analytics have dramatically enhanced the sensitivity, accuracy, and clinical value of liquid biopsy tests.

Key advancements include:

High-sensitivity ctDNA detection

Multigene cancer panels

Exosome profiling for early recurrence detection

AI-driven mutation analytics

Ultra-low frequency variant detection

A notable industry example occurred in August 2024, when Hitachi High-Tech Corporation entered a strategic partnership with Gencurix, Inc. to combine digital technologies with advanced biomarker discovery to enhance cancer molecular diagnostics.

As diagnostics become more precise and scalable, liquid biopsies are increasingly integrated into oncology workflows worldwide.

3. Global Shift Toward Non-Invasive Diagnostic Techniques

Today’s healthcare landscape is prioritizing minimally invasive, home-based, and patient-friendly solutions. Liquid biopsy fits seamlessly into this paradigm.

Patients with late-stage cancer or complex comorbidities often cannot undergo surgical biopsies. Liquid biopsy offers a safer alternative with significant advantages:

Short recovery time

Feasibility for frequent sampling

Suitability for elderly or fragile patients

Applicability in decentralized care settings

As outpatient and telemedicine-based diagnostics expand, liquid biopsy adoption is expected to skyrocket.

Regional Market Insights

United States: A Global Leader in Liquid Biopsy Innovation

The United States maintains its position as the world’s most advanced liquid biopsy market due to:

High cancer prevalence

Strong biotechnology ecosystem

Extensive R&D investments

Rapid FDA approvals

Strong integration with precision medicine

In February 2024, Myriad Genetics, Inc. announced the acquisition of key molecular diagnostic assets from Intermountain Health, strengthening its liquid biopsy and tumor profiling capabilities.

With major players like Guardant Health, Exact Sciences, Thermo Fisher, and Illumina headquartered in the U.S., innovation continues to accelerate, supporting national and global market growth.

Germany: A European Powerhouse in Precision Diagnostics

Germany dominates Europe’s liquid biopsy market due to:

A robust healthcare infrastructure

High adoption of precision molecular testing

Strong academic–industry collaborations

Government support for oncology innovation

In September 2024, PreAnalytiX GmbH introduced the PAXgene Urine Liquid Biopsy Set, enabling reliable cfDNA analysis from urine—a major advancement expanding biomarker detection beyond blood-based approaches.

Germany’s clear regulatory pathways and technological leadership make it a cornerstone of Europe’s diagnostic evolution.

China: Fastest-Growing Player in Asia-Pacific

China’s liquid biopsy market is expanding at an extraordinary pace, fueled by:

A high cancer burden

Growing demand for early detection

Government-driven healthcare modernization

Strong domestic biotechnology investment

A major milestone was reached in August 2023, when China’s NMPA approved sunvozertinib for advanced NSCLC patients with EGFR exon 20 mutations—highlighting the growing role of companion diagnostics in personalized cancer therapy.

China is rapidly establishing itself not just as a market, but as a global innovator in molecular diagnostics.

Brazil: Leading Liquid Biopsy Adoption in Latin America

Brazil is spearheading Latin America’s adoption of advanced cancer diagnostics, supported by:

Increasing healthcare expenditure

Widespread awareness of cancer detection

Investments in biotechnology research

Governmental initiatives to expand access

As Brazil continues modernizing oncology infrastructure, liquid biopsy is becoming a preferred choice for early cancer detection and disease monitoring.

Key Recent Developments in the Liquid Biopsy Industry

F. Hoffmann-La Roche Ltd.

US FDA approval (2020) for expanded NSCLC companion diagnostics

June 2022 partnership with LCRF and LCMC for early lung cancer driver mutation detection

Bio-Rad Laboratories

ddPCR technology enabling high-precision CTC and cfDNA analysis

Thermo Fisher Scientific

August 2023 launch of DNA/RNA MRD assays

2021 collaboration with AstraZeneca for NGS-based CDx development

Biocept Inc.

July 2021 South Korean patent for Primer-Switch mutation detection technology

Guardant Health

FDA approval for Guardant360 CDx (2021, 2023)

Expansion of Reveal tests for colorectal cancer MRD monitoring

Illumina, Inc.

2023 launch of TruSight Oncology 500 ctDNA v2

Partnerships advancing NIPT and precision oncology

QIAGEN N.V.

Launch of QIAseq targeted cfDNA panels in 2023

Multiple collaborations for ultra-sensitive NGS technology

Exact Sciences Corporation

Expansion into hereditary cancer testing through Prevention Genetics acquisition

Global Market Segmentation

By Product

Kits & Reagents

Platforms & Instruments

Services

By Application

Cancer Therapeutics

Reproductive Health

Other Therapeutic Uses

By Circulating Biomarker

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Cell-Free DNA (cfDNA)

By End User

Hospitals

Diagnostic Laboratories

Point-of-Care Testing

Academic Institutes

Others

By Region

Americas: U.S., Canada, Mexico, Brazil

Europe: U.K., Germany, France, Italy, Spain, Netherlands

Asia-Pacific: China, Japan, India, South Korea, Australia

Middle East & Africa: UAE, South Africa

Rest of World

Company Profiles Covered

F. Hoffmann-La Roche Ltd.

Bio-Rad Laboratories

Thermo Fisher Scientific Inc.

Johnson & Johnson

Biocept Inc.

Guardant Health

Illumina, Inc.

Laboratory Corporation of America Holdings

QIAGEN N.V.

Exact Sciences Corporation

Final Thoughts: The Future of Diagnostics Is Non-Invasive—and Liquid Biopsy Leads the Way

The global liquid biopsy market is undergoing a paradigm shift, evolving from a niche diagnostic tool to a mainstream clinical necessity. As cancer cases rise and precision medicine becomes a global priority, liquid biopsy technologies will play a central role in enabling earlier detection, better monitoring, and personalized treatment for millions of patients worldwide.

With the market projected to reach US$ 15.46 billion by 2033, increasing collaboration between biotechnology firms, healthcare institutions, and regulatory bodies will accelerate innovation even further. From ctDNA sequencing breakthroughs to AI-powered biomarker analysis, the next decade promises a revolutionary transformation in how the world approaches disease detection—and liquid biopsies will be at the heart of that evolution.